<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Zoetis Inc — News on 6ix</title>
<link>https://6ix.com/company/zoetis-inc</link>
<description>Latest news and press releases for Zoetis Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/zoetis-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ddbe78dffbe2df124db3.webp</url>
<title>Zoetis Inc</title>
<link>https://6ix.com/company/zoetis-inc</link>
</image>
<item>
<title>Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-to-host-webcast-and-conference-call-on-first-quarter-2026-financial-results-74</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-to-host-webcast-and-conference-call-on-first-quarter-2026-financial-results-74</guid>
<pubDate>Thu, 02 Apr 2026 12:30:00 GMT</pubDate>
<description>PARSIPPANY, N.J., April 02, 2026--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2026 financial results and respond to questions from financial analysts.</description>
</item>
<item>
<title>Zoetis to Participate in the KeyBanc Capital Markets Healthcare Forum</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-to-participate-in-the-keybanc-capital-markets-healthcare-forum-1</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-to-participate-in-the-keybanc-capital-markets-healthcare-forum-1</guid>
<pubDate>Thu, 12 Mar 2026 12:30:00 GMT</pubDate>
<description>PARSIPPANY, N.J., March 12, 2026--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026 at 10:30 a.m. ET.</description>
</item>
<item>
<title>Zoetis expands Human-Animal Bond Certification scholarship to include veterinary technician students</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-expands-human-animal-bond-certification-scholarship-to-include-veterinary-technician-students</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-expands-human-animal-bond-certification-scholarship-to-include-veterinary-technician-students</guid>
<pubDate>Tue, 10 Mar 2026 11:00:00 GMT</pubDate>
<description>NAVC and HABRI are proud to announce that Zoetis, a leading animal health company, has pledged its continued support for veterinary students across the United States by offering freeHuman-Animal Bond Certification throughout 2026. New this year, the scholarship is now available to veterinary technician students, who play a vital role on the care team, often serving as the primary point of care for clients and their pets. The expansion of this program to include veterinary technician students sig</description>
</item>
<item>
<title>Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-to-acquire-animal-genomics-business-from-neogenr-accelerating-precision-animal-health-innovation-1</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-to-acquire-animal-genomics-business-from-neogenr-accelerating-precision-animal-health-innovation-1</guid>
<pubDate>Mon, 02 Mar 2026 12:00:00 GMT</pubDate>
<description>PARSIPPANY, N.J., March 02, 2026--Zoetis to acquire animal genomics business from Neogen, strengthening the company's leadership in Precision Animal Health</description>
</item>
<item>
<title>Neogen Announces Sale of Genomics Business to Zoetis</title>
<link>https://6ix.com/company/zoetis-inc/news/neogen-announces-sale-of-genomics-business-to-zoetis-1</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/neogen-announces-sale-of-genomics-business-to-zoetis-1</guid>
<pubDate>Mon, 02 Mar 2026 12:00:00 GMT</pubDate>
<description>LANSING, Mich., March 02, 2026--Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc. ("Zoetis"), the world’s leading animal health company, for $160 million, subject to customary closing adjustments. The planned divestiture, which had been previously announced, was part of the company’s portfolio review strategy to simplify the business and focus on core str</description>
</item>
<item>
<title>Zoetis to Participate in the Bank of America Securities 2026 Animal Health Summit</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-to-participate-in-the-bank-of-america-securities-2026-animal-health-summit</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-to-participate-in-the-bank-of-america-securities-2026-animal-health-summit</guid>
<pubDate>Tue, 24 Feb 2026 13:30:00 GMT</pubDate>
<description>PARSIPPANY, N.J., February 24, 2026--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2026 Animal Health Summit on Thursday, February 26, 2026 at 1:15 p.m. ET. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company.</description>
</item>
<item>
<title>Zoetis Reports Fourth Quarter and Full Year 2025 Results</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-reports-fourth-quarter-full-120000511</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-reports-fourth-quarter-full-120000511</guid>
<pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
<description>PARSIPPANY, N.J., February 12, 2026--Zoetis Inc. (NYSE: ZTS), the world's leading animal health company, today reported its financial results for the fourth quarter and full year 2025 and provided full year guidance for 2026.</description>
</item>
<item>
<title>Zoetis Declares Second Quarter 2026 Dividend</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-declares-second-quarter-2026-211500128</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-declares-second-quarter-2026-211500128</guid>
<pubDate>Thu, 05 Feb 2026 21:15:00 GMT</pubDate>
<description>PARSIPPANY, N.J., February 05, 2026--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company’s common stock as of the close of business on Monday, April 20, 2026.</description>
</item>
<item>
<title>Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-host-webcast-conference-call-133000201</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-host-webcast-conference-call-133000201</guid>
<pubDate>Tue, 30 Dec 2025 13:30:00 GMT</pubDate>
<description>PARSIPPANY, N.J., December 30, 2025--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2025 financial results and respond to questions from financial analysts.</description>
</item>
<item>
<title>Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-participate-44th-annual-j-133000360</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-participate-44th-annual-j-133000360</guid>
<pubDate>Thu, 18 Dec 2025 13:30:00 GMT</pubDate>
<description>PARSIPPANY, N.J., December 18, 2025--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT.</description>
</item>
<item>
<title>Zoetis Announces Pricing of $1.75 Billion Convertible Senior Notes Offering</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-announces-pricing-1-75-061500927</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-announces-pricing-1-75-061500927</guid>
<pubDate>Tue, 16 Dec 2025 06:15:00 GMT</pubDate>
<description>PARSIPPANY, N.J., December 16, 2025--Zoetis Inc. (NYSE: ZTS) (the "Company" or "Zoetis") today announced that it has priced its previously announced offering of $1.75 billion aggregate principal amount of 0.25% convertible senior notes due 2029 (the "Notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the "Securities Act"). Zoetis has also granted the initial purchasers of the Notes an</description>
</item>
<item>
<title>Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-announces-proposed-1-75-120900790</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-announces-proposed-1-75-120900790</guid>
<pubDate>Mon, 15 Dec 2025 12:09:00 GMT</pubDate>
<description>PARSIPPANY, N.J., December 15, 2025--Zoetis Inc. (NYSE: ZTS) (the "Company" or "Zoetis") today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the "Notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the "Securities Act"). Zoetis also intends to grant the initial purchasers of the Notes an o</description>
</item>
<item>
<title>Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-declares-first-quarter-2026-211500550</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-declares-first-quarter-2026-211500550</guid>
<pubDate>Thu, 11 Dec 2025 21:15:00 GMT</pubDate>
<description>PARSIPPANY, N.J., December 11, 2025--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 20, 2026.</description>
</item>
<item>
<title>Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-receives-health-canada-approval-133000277</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-receives-health-canada-approval-133000277</guid>
<pubDate>Fri, 05 Dec 2025 13:30:00 GMT</pubDate>
<description>PARSIPPANY, N.J., December 05, 2025--Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation.</description>
</item>
<item>
<title>Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-highlights-r-d-leadership-123000010</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-highlights-r-d-leadership-123000010</guid>
<pubDate>Tue, 02 Dec 2025 12:30:00 GMT</pubDate>
<description>PARSIPPANY, N.J., December 02, 2025--Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health.</description>
</item>
<item>
<title>Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-receives-european-commission-marketing-211500304</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-receives-european-commission-marketing-211500304</guid>
<pubDate>Wed, 26 Nov 2025 21:15:00 GMT</pubDate>
<description>PARSIPPANY, N.J., November 26, 2025--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs.</description>
</item>
<item>
<title>Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-participate-piper-sandler-37th-133000903</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-participate-piper-sandler-37th-133000903</guid>
<pubDate>Thu, 20 Nov 2025 13:30:00 GMT</pubDate>
<description>PARSIPPANY, N.J., November 20, 2025--Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts.</description>
</item>
<item>
<title>Zoetis to Host Innovation Webcast</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-host-innovation-webcast-133000941</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-host-innovation-webcast-133000941</guid>
<pubDate>Wed, 19 Nov 2025 13:30:00 GMT</pubDate>
<description>PARSIPPANY, N.J., November 19, 2025--Zoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Executive Vice President and Chief Financial Officer; Rob Polzer, Ph.D., Executive Vice President and President of Research and Development; and Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic), Senior Vice President of Global Therapeutics. As previously announced, Dr. Esch will succeed Dr</description>
</item>
<item>
<title>Zoetis Announces Third Quarter 2025 Results</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-announces-third-quarter-2025-120000789</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-announces-third-quarter-2025-120000789</guid>
<pubDate>Tue, 04 Nov 2025 12:00:00 GMT</pubDate>
<description>PARSIPPANY, N.J., November 04, 2025--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025.</description>
</item>
<item>
<title>Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026</title>
<link>https://6ix.com/company/zoetis-inc/news/zoetis-announces-retirement-rob-polzer-211500149</link>
<guid isPermaLink="true">https://6ix.com/company/zoetis-inc/news/zoetis-announces-retirement-rob-polzer-211500149</guid>
<pubDate>Mon, 03 Nov 2025 21:15:00 GMT</pubDate>
<description>PARSIPPANY, N.J., November 03, 2025--Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 20</description>
</item>
</channel>
</rss>